1. Evolving Concepts in the Management of Head and Neck Cancers

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Immune Checkpoint Inhibition

4. Novel Immunotherapeutic Approaches

5. Current Standard of Care Second-Line for Platinum-Refractory SCCHN

6. CheckMate 141 Study Design

7. CheckMate Year OS

8. CheckMate 141 Treatment-Related Adverse Events

9. CheckMate-141 OS at 2-Year Follow-Up

10. OS Benefit in Patients With PD-L1+ Tumors 6-Month vs 2-Year Follow-Up

11. OS Benefit in Patients With PD-L1- Tumors 6-Month vs 2-Year Follow-Up

12. PD-L1 Status in Patient Selection

13. Platinum-Refractory Patients Locally Advanced vs Recurrent Metastatic Setting

14. Pembrolizumab Background

15. KEYNOTE-040 Study Design

16. KEYNOTE-040 Efficacy and Safety in the ITT Population

17. CheckMate-141 vs KEYNOTE-040

18. KEYNOTE-040 Update Efficacy in PD-L1 CPS ≥ 1 and TPS ≥ 50% Populations

19. Combination Immunotherapies Rationale

20. Combination Immunotherapies Second-Line for SCCHN

21. Combination Immunotherapies First-Line for SCCHN

22. Pseudoprogression and Hyperprogression

23. Treatment Beyond Progression Continued Immunotherapy vs Salvage Chemotherapy

24. Immune Checkpoint Inhibition Locally Advanced SCCHN

25. Caution in the Development of Novel Targets PD-1 Inhibitors Plus Epacadostat

26. Targets on the Horizon STAT3

27. Targets on the Horizon OX40

28. Practicalities of Use

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)